- Trials with a EudraCT protocol (81)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
81 result(s) found for: Waist hip ratio.
Displaying page 1 of 5.
EudraCT Number: 2005-003797-25 | Sponsor Protocol Number: GH100-013 | Start Date*: 2005-12-09 |
Sponsor Name:ConjuChem, Inc. | ||
Full Title: A Multicenter, Randomized, Placebo-controlled, Double-blind Phase 2 Study to Evaluate the Efficacy and Safety of CJC-1295 administered for 12 weeks in HIV-Infected Patients with HIV-associated Visc... | ||
Medical condition: Patients 18 to 65 years old with HIV-associated visceral obesity, on a stable antiviral regimen for at least 6 weeks, with a viral load ≤1,000 copies/mL and CD4 count ≥200 cells/mm3, a body mass in... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004275-70 | Sponsor Protocol Number: GPD-01-01 | Start Date*: 2016-01-08 |
Sponsor Name:Gene PreDiT SA | ||
Full Title: Influence of single nucleotide polymorphisms of carboxypeptidase D (CPD) gene on body weight and fat mass reduction by perindopril in obese subjects: A phase II, multicenter, double-blind study. | ||
Medical condition: Body weight and fat mass reduction by perindopril in obese subjects | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-005444-88 | Sponsor Protocol Number: TH9507-CTR-1011 | Start Date*: 2007-01-16 | |||||||||||
Sponsor Name:Theratechnologies Inc. | |||||||||||||
Full Title: A Multicenter, Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess A... | |||||||||||||
Medical condition: HIV-associated lipodystrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) GB (Completed) DE (Prematurely Ended) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003426-24 | Sponsor Protocol Number: CTU079G | Start Date*: 2013-02-13 |
Sponsor Name:Riemser Pharma GmbH | ||
Full Title: A multicentre double blind placebo controlled clinical trial to assess efficacy and safety of Alvalin® (cathine hydrochloride) vs. placebo in 265 obese patients/group with a body mass index (BMI) b... | ||
Medical condition: diet-related obesity diagnosed by BMI of 30 to 45 kg/m² | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-002230-37 | Sponsor Protocol Number: CLAF237ANL05T | Start Date*: 2013-12-19 |
Sponsor Name:Erasmus Medical Center | ||
Full Title: “Novel Approach to Detect the Detailed Effects of Vildagliptin on Beta-cell Dynamics in Patients with Early-onset Type 2 Diabetes” | ||
Medical condition: impaired fasting glucose/impaired glucose tolerance, prediabetes | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-000440-10 | Sponsor Protocol Number: CADPT02A12001 | Start Date*: 2020-02-21 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: NASH EXploratory Single and COmbination Treatment (NEXSCOT): An open label, multicenter, platform study to evaluate the safety, tolerability, pharmacokinetics and efficacy of various single and com... | |||||||||||||
Medical condition: non-alcoholic fatty liver disease (NAFLD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010116-15 | Sponsor Protocol Number: CTU 052 D | Start Date*: 2010-05-31 |
Sponsor Name:RIEMSER Arzneimittel AG | ||
Full Title: A multicentre double blind placebo controlled clinical dose- finding study for three doses of Antiadipositum X 112 T® (Cathine-hydrochloride) vs. placebo in 240 patients with a body mass index (BMI... | ||
Medical condition: diet-related obesity diagnosed by BMI of 30 to 40 kg/m² or diet-related obesity diagnosed by BMI of 27 to 40 kg/m² in patient with coexisting risk factors like hyperlipidaemia, type 2 diabetes mell... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001080-24 | Sponsor Protocol Number: NL76906.068.21 | Start Date*: 2021-04-08 |
Sponsor Name:Maastricht University | ||
Full Title: The effect of plant stanol ester consumption on the vaccination response to a COVID-19 vaccine | ||
Medical condition: COVID-19 vaccination respons of people with BMI 27-35 kg/m2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2007-002600-18 | Sponsor Protocol Number: 43/2007/O/Sper | Start Date*: 2007-06-05 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: EVALUATION OF THE RELATIONSHIP BETWEEN INFLAMMATION-PHYSICAL ACTIVITY AND THE ACTIVITY OF THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS | |||||||||||||
Medical condition: Abdominal obesity with metabolic syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016921-32 | Sponsor Protocol Number: HSJD-OB-TRP | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Fundació Sant Joan de Déu | |||||||||||||
Full Title: A phase II, randomized, double-blind, placebo-controlled, in parallel groups clinical trial to assess the safety and efficacy of dietary supplementation with tryptophan to achieve weight loss, and ... | |||||||||||||
Medical condition: obesity | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017080-41 | Sponsor Protocol Number: GWMD09112 | Start Date*: 2010-04-19 | |||||||||||
Sponsor Name:GW Pharma Ltd. | |||||||||||||
Full Title: A randomised, partially-blind, placebo-controlled, pilot, dose-ranging study to assess the effect of cannabidiol (CBD) on liver fat levels in subjects with fatty liver disease. | |||||||||||||
Medical condition: Subjects with fatty liver disease (≥ 5% liver fat levels). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000872-41 | Sponsor Protocol Number: BGP-15-CLIN-IR01 | Start Date*: 2005-04-19 |
Sponsor Name:N-Gene Research & Development Ltd. | ||
Full Title: RANDOMIZED DOUBLE-BLIND, MULTIPLE DOSE, PLACEBO-CONTROLLED STUDY TO DETERMINE THE INSULIN SENSITIZING EFFECT OF BGP-15 IN PATIENTS WITH INSULIN RESISTANCE | ||
Medical condition: The metabolic syndrome is characterized by central obesity, atherogenic dyslipidemia, insulin resistance or glucose intolerance; prothrombotic state; raised blood pressure, proinflammatory state | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-006114-14 | Sponsor Protocol Number: 62326B1658 | Start Date*: 2012-04-17 |
Sponsor Name:Research and Development department | ||
Full Title: “Effects of testosterone on glycaemic control and other Cardiovascular Risk factors in Hypogonadal Men with uncontrolled Type 2 Diabetes: A randomized double – blinded placebo controlled add on tr... | ||
Medical condition: Hypogonadism Type 2 Diabetes Cardiovascular risk | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004430-96 | Sponsor Protocol Number: 201600107 | Start Date*: 2017-12-11 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Short-term Testosterone replacement in testicular cancer survivors to treat overweight and improve cardiometabolic risk | ||
Medical condition: Testicular cancer | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002365-19 | Sponsor Protocol Number: 2 | Start Date*: 2018-08-22 |
Sponsor Name:Line Velling Magnussen | ||
Full Title: Muscle strength and -mass after bariatric surgery - a possible effect of testosterone replacement therapy? Randomized, placebo-controlled and double-blinded study | ||
Medical condition: General aim To investigate the effect and clinical relevance of testosterone therapy combined with exercise and diet counselling in hypogonadal men undergoing bariatric surgery. Objectives To eval... | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: DK (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2010-020458-33 | Sponsor Protocol Number: GWMD1092 | Start Date*: 2010-08-05 | |||||||||||
Sponsor Name:GW Pharma Ltd. | |||||||||||||
Full Title: A randomised, double blind, placebo controlled, parallel group, pilot study of 1:1 and 20:1 ratio of formulated GW42003: GW42004 plus GW42003 and GW42004 alone in the treatment of dyslipidaemia in ... | |||||||||||||
Medical condition: Dyslipidaemia in subjects with type 2 diabetes who have failed to achieve satisfactory lipid control with existing therapies. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012049-46 | Sponsor Protocol Number: IEO S480/209 | Start Date*: 2010-07-29 | |||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
Full Title: Phase III, randomized, double blind trial on Vitamin D supplementation for resected stage II melanoma patients. | |||||||||||||
Medical condition: melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003417-32 | Sponsor Protocol Number: NN2211-1572 | Start Date*: 2006-05-08 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on glycaemic control after once daily administration of liraglutide in combination with metformin versus metformin monotherapy versus metf... | |||||||||||||
Medical condition: Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) HU (Completed) SE (Completed) DK (Completed) GB (Completed) SK (Completed) BE (Completed) ES (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001144-71 | Sponsor Protocol Number: D6160C00032 | Start Date*: 2004-10-22 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Added to the Therapy of Pat... | ||
Medical condition: Patients diagnosed with type 2 diabetes and treated with a single or multiple oral antidiabetic agents | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-018720-12 | Sponsor Protocol Number: pb01 | Start Date*: 2010-04-22 |
Sponsor Name:Swedish Pituitary Study group | ||
Full Title: Behandling med kabergolin hos patienter med ACTH-beroende Cushing´s syndrom (treatment with cabergoline in patients with ACTH-dependent Cushing´s syndrome | ||
Medical condition: A) Men and women aged 18 to 75 years with hypercortisolism due to ACTH-dependent Cushing's syndrome will be treated in the period between diagnosis and planned surgery or radiation therapy. B) Men... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
